Blue Wave Semiconductors has unveiled the Pulsed Laser Deposition (PLD) System, a PVD platform designed for the ...

New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the ...

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision ...

Making stuff cool and keeping it that way has been a pretty essential part of human civilization for thousands of years, with ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events ---- ...

CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; ...

A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...

Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich’s ataxia (FA), emphasizing ...

Peptide therapeutics require tailored ADME strategies to address stability, supporting more effective and reliable drug ...

According to a recent report from ETH Zurich (the Swiss Federal Institute of Technology, “policymakers should not rely on, or ...